Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross ProceedsGlobeNewsWire • 11/21/23
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with NamodenosonBusiness Wire • 11/21/23
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on TrackBusiness Wire • 11/01/23
Can-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 10/30/23
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of ActionBusiness Wire • 10/30/23
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer DrugsBusiness Wire • 10/26/23
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese CompaniesBusiness Wire • 10/09/23
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)Business Wire • 09/27/23
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual ConferenceBusiness Wire • 09/07/23
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesBusiness Wire • 08/31/23
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe SyndromeBusiness Wire • 08/24/23
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with PsoriasisBusiness Wire • 08/18/23
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer FoundationBusiness Wire • 07/17/23
Can-Fite Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration PlanBusiness Wire • 06/29/23
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with NamodenosonBusiness Wire • 06/13/23
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in BostonBusiness Wire • 06/02/23
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical UpdateBusiness Wire • 06/01/23
Can-Fite: Namodenoson's Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)Business Wire • 05/30/23
Can-Fite: Presenting Namodenoson's New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023Business Wire • 05/15/23